BlueCross BlueShield Federal Employee Program

# TEPMETKO
# (tepotinib)

## RATIONALE FOR INCLUSION IN PA PROGRAM

### Background

Tepmetko (tepotinib) is a kinase inhibitor that targets mesenchymal-epithelial transition (MET), including variants with exon 14 skipping alterations. Tepmetko inhibits hepatocyte growth factor (HGF)-dependent and -independent MET phosphorylation and MET-dependent downstream signaling pathways. Tepmetko inhibits tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent tumor cells (1).

### Regulatory Status

FDA-approved indication: Tepmetko is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations (1).

Off-Label Use: (2-3)

1. NSCLC tumors with high-level MET amplification

Interstitial lung disease (ILD)/pneumonitis, which can be fatal, occurred in patients taking Tepmetko. Patients taking Tepmetko should be monitored for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Tepmetko should be permanently discontinued if no other potential causes of ILD/pneumonitis are identified (1).

Hepatotoxicity occurred in patients treated with Tepmetko. Liver function tests (including ALT, AST, and total bilirubin) should be monitored prior to the start of Tepmetko, every 2 weeks during the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Tepmetko should be withheld, dose reduced, or permanently discontinued based on severity (1).

Tepmetko can cause fetal harm when administered to a pregnant woman. Female patients of reproductive potential should be advised to use effective contraception during treatment with Tepmetko and for 1 week after the final dose. Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment with Tepmetko and for 1 week after the final dose (1).

BlueCross BlueShield
Federal Employee Program

# TEPMETKO
# (tepotinib)

The safety and efficacy of Tepmetko in pediatric patients have not been established (1).


**Summary**

Tepmetko (tepotinib) is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. In addition, the National Comprehensive Cancer Network (NCCN) Guidelines support the off-label use of Tepmetko for metastatic NSCLC with high-level MET amplification. Tepmetko has warnings for interstitial lung disease (ILD)/pneumonitis, hepatotoxicity, and embryo-fetal toxicity. The safety and efficacy of Tepmetko in pediatric patients have not been established (1).


Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Tepmetko while maintaining optimal therapeutic outcomes.

**References**


1. Tepmetko [package insert]. Rockland, MA: EMD Serono, Inc.; February 2024.
2. NCCN Clinical Practice Guidelines in Oncology® Non-Small Cell Lung Cancer (Version 3.2025). National Comprehensive Cancer Network, Inc. January 2025. Accessed on January 14, 2025.
3. NCCN Drugs & Biologics Compendium® Tepotinib 2025. National Comprehensive Cancer Network, Inc. Accessed on January 14, 2025.